Screener
Immix Biopharma, Inc. IMMX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Operating expenses: | ||
| General and administrative expenses | $4,823,378 | $2,707,851 |
| Research and development | 5,980,477 | 1,975,074 |
| Total operating expenses | 10,803,855 | 4,682,925 |
| Loss from operations | (10,803,855) | (4,682,925) |
| Other income (expense): | ||
| Interest income | 717,168 | 150,219 |
| Total other income (expense), net | 717,168 | 150,219 |
Document
FAQ
- What is Immix Biopharma, Inc.'s other operating expenses?
- Immix Biopharma, Inc. (IMMX) reported other operating expenses of $10.8M in Q1 2026.
- How has Immix Biopharma, Inc.'s other operating expenses changed year-over-year?
- Immix Biopharma, Inc.'s other operating expenses increased by 130.7% year-over-year, from $4.68M to $10.8M.
- What is the long-term trend for Immix Biopharma, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s other operating expenses has grown at a 117.0% compound annual growth rate (CAGR), from $1.35M to $29.96M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Immix Biopharma, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude